Arbiter Partners Capital Management LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 28,095 shares of the company's stock, valued at approximately $433,000. Inhibrx comprises approximately 0.3% of Arbiter Partners Capital Management LLC's portfolio, making the stock its 18th biggest holding. Arbiter Partners Capital Management LLC owned about 0.19% of Inhibrx at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the business. Exchange Traded Concepts LLC bought a new position in shares of Inhibrx in the 4th quarter valued at approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Inhibrx during the fourth quarter valued at approximately $348,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Inhibrx in the fourth quarter valued at approximately $47,000. Rhumbline Advisers acquired a new stake in shares of Inhibrx in the fourth quarter worth $228,000. Finally, New York State Common Retirement Fund acquired a new position in Inhibrx during the 4th quarter worth $53,000. Institutional investors and hedge funds own 82.46% of the company's stock.
Analyst Ratings Changes
Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
Check Out Our Latest Analysis on Inhibrx
Inhibrx Price Performance
NASDAQ:INBX traded up $0.29 during trading hours on Friday, hitting $11.61. 103,135 shares of the company traded hands, compared to its average volume of 206,743. The firm has a 50-day moving average of $13.25 and a 200 day moving average of $14.31. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $35.08.
Inhibrx (NASDAQ:INBX - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. Analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current year.
About Inhibrx
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
See Also
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
